

# Body weight support treadmill training on children with ataxia

<b>Submission date</b> 17/01/2021	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 27/01/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 10/04/2025	<b>Condition category</b> Nervous System Diseases	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Ataxia is a term for a group of disorders that affect co-ordination, balance and speech. Any part of the body can be affected, but people with ataxia often have difficulties with: balance and walking, speaking, swallowing, tasks that require a high degree of control, such as writing and eating, vision.

The present project aims to design a functional intensive rehabilitation program for children ataxia and propose feasible in clinical practice and goal directed approaches for promoting functional rehabilitation. The proposed program will utilize partial body weight support strategies and motor dual task training using a treadmill.

### Who can participate:

Children aged 8-18 years old with ataxia as a result of congenital, acquired or genetic damage, with GMFCS II-IV

### What does this study involve?

This study will last approximately 3 months. In this period children will need to be assessed in terms of motor and functional skills in 3 different periods. According to the allocated group, children will either continue their regular therapeutic program or will combine their regular therapeutic program with a functional 4-week PBWSTT program.

### What are the possible benefits and risks of participating?

Participation will be voluntary so there will be no financial benefit since this research is not funded. However, the information we will get from this research will be for the future benefit of children with ataxia disorder. This contribution will help improve clinical evaluation and design of effective therapeutic interventions. This research involves minimal risk or danger. All measurements from the scales and assessment tools are valid and reliable, safe to use and all tests are always performed under the supervision and instructions of the physiotherapist. The same applies to physiotherapy intervention that involves activities, which will always be performed under the supervision of a physiotherapist.

### Where is the study run from?

Department of Physiotherapy of the University of West Attica (UniWA) (Greece)

When is the study starting and how long is it expected to run for?  
February 2020 to March 2023

Who is funding the study?  
Investigator initiated and funded

Who is the main contact?  
Alexandra Lepoura, alepoura@uniwa.gr

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mrs Alexandra Lepoura

**ORCID ID**  
<https://orcid.org/0000-0002-3353-0388>

**Contact details**  
67 Pentelis Str  
Kinitro kai Kinisi  
Marousi - Athens  
Greece  
15126  
+30 6948620233  
alepoura@uniwa.gr

**Type(s)**  
Public

**Contact name**  
Prof Vasiliki Sakellari

**ORCID ID**  
<https://orcid.org/0000-0002-9481-996X>

**Contact details**  
Physiotherapy Department  
University of West Attica  
Egaleo  
Greece  
12243  
+30 6979033952  
vsakellari@uniwa.gr

**Type(s)**  
Public

**Contact name**

Dr Sofia Lampropoulou

**ORCID ID**

<https://orcid.org/0000-0002-2095-5184>

**Contact details**

Department of Physiotherapy  
School of Health Rehabilitation Science  
University of Patras  
Psaron 6, Myrtia  
Aigio  
Greece  
25100  
+30 6946749576  
szlampropoulou@gmail.com

**Type(s)**

Public

**Contact name**

Dr Marianna Papadopoulou

**ORCID ID**

<https://orcid.org/0000-0002-0163-7455>

**Contact details**

Physiotherapy Department, University of West Attica  
Agiou Spiridonos 28  
Egaleo  
Greece  
12243  
+30 210 5387485  
mpapad@uniwa.gr

## Additional identifiers

## Study information

**Scientific Title**

The effectiveness of a Functional Partial Body Weight Support Treadmill Training (FPBWSTT) on motor and functional skills of children with ataxia

**Acronym**

FPBWSTT and Child Ataxia

**Study objectives**

Current hypothesis as of 29/12/2021:

A great heterogeneity characterizes the pediatric population with ataxia, which has been studied poorly, in terms of both evaluation and intervention. The lack of postural control and

coordination, in addition with features of the 'ataxic' gait are linked with functional limitations. Studies on physiotherapy interventions for children with ataxia are highly needed for identifying optimal training strategies for improving motor and functional related skills.

The primary objective of the proposed protocol is to evaluate the effect of the proposed 4-week intensive therapeutic program on motor tasks and functional skills related to standing and gait. We hypothesize that the suggested therapeutic functional program is more effective than typical physiotherapy in improving gross motor function in standing and walking when applied in children with ataxia, aged 8 to 18 years.

Secondary objectives include evaluating the effect from the application of the proposed program on functional skills in balance, self-selected cadence, dynamic balance control, physical condition and endurance, ataxia features and gait analysis characteristics. Further objectives of the study refer to the long-term effect of the 4week therapeutic program in a time period of 2 months and to understand the effect of such intervention and clinically interpret its results for future therapeutic purposes.

---

Previous hypothesis:

Functional based PBWSTT improves motor and functional skills more than a conventional physiotherapy program in children with ataxia.

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

1. Approved 14/04/2020, University General Hospital Attikon- Scientific Council (1 Str Rimini, Chaidari, 12462, Athens, Greece; +30210-5831693/+30210-5831698; no email contact), ref: Γ ΠΑΙΔ, ΕΒΔ 149/20-03-2020

2. Approved 26/04/2021, Ethics Committee of University of West Attica (University of West Attica

Agiou Spiridonos 28, 12243 Egaleo, Athens, Greece, Tel.: +302105387294; ethics@uniwa.gr), ref: 14η/26-04-2021

### **Study design**

Interventional stratified randomized controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Quality of life

### **Health condition(s) or problem(s) studied**

Physiotherapy intervention for children with ataxia

### **Interventions**

Current intervention as of 29/12/2021:

The recruitment of the population will be carried out by private and public therapeutic areas. A group of children with ataxia, aged 8 to 18 years, will participate.

An information sheet and consent form will be provided to all participants. After obtaining a signed consent form, subjects will be randomly assigned to either intervention group (functional PBWSTT) or control group (conventional physiotherapy).

Assessment will be obtained in three time periods: prior to the experiment, after the experiment and 2 months after the experiment. For the anthropometric data acquisition, precision equipment will be used. Gait training will be performed using a Lite Gait LGI 200P system accompanied by a Gait keeper Treadmill system with a low start walking speed (0.1 m/h) and built-in sensors for data recording. Gait Sens 2000 and BiSymSoftware will be used. Gait and posture biomechanical data will be acquired by 10 Vicon Cameras (6MXT10 and 4 Verov2.2) at 100 Hz and 2 Basler (Pentaxlenses) digital video cameras 50 Hz. ViconNexus 2.9.1 recording software for the 16 passive reflective markers gap-filling and data filtering will be used. Further processing and extraction of data will be made through Vicon Polygon 3.5.1 software.

#### Functional based PBWSTT Intervention:

The proposed protocol will be based on the implementation of the protocol of Bjornson et al. (2019) with modifications based on the findings of the literature, alongside functional dual-task activities. All the phases of the protocol will be administered in PBWS. The suspension will be set to <40% of body weight. Twenty 45-minute sessions will be completed over a period of 4 weeks (5 days per week). The period of 45 min will be composed of two phases:

1. Phase 1: Walking training on the treadmill. The treadmill gait training through short burst interval PBWSTT will last 30 total minutes. The speed of the treadmill will be individualized for each participant, employing baseline self-selected and fast walking speed over ground (10-m walk test), thus standardizing the dosing of training speeds for high and low-speed walking levels. Starting tread speeds for high and low walking treadmill speed will be 75% of each participant's baseline walking over-ground levels. High-speed and low-speed intervals will be alternated every 30 sec. High speed will be gradually increased by 5% between sessions, while low speed remains constant throughout the protocol. The child will be informed of the speed intervals during the gait. In the 30 minutes of gait training there will be short breaks, whenever needed during which the child will stand upright in a physical position. The goal is to achieve a total of 20 minutes of walking. The handles will not be used throughout the gait training to enhance the reciprocal arm swing as much as possible.
2. Phase 2: Functional activities - dual task. The Functional dual training will last 15 total minutes and will be delivered during constant low-speed gait on the treadmill (treadmill pace step). Functional exercises during gait will simulate the needs of daily life and they will consist of walking in different directions, steps to the side, back steps, walking and crossing obstacles, walking and catching and throwing a ball. In each session, 3 of the 6 activities will be applied in a rotating cycle, each of which will last 5 minutes. In each session, the performance of each participant will be recorded and the physiotherapist will encourage the gradual improvement of the motor performance in each activity with verbal and visual guidance.

#### Usual/typical care:

Participants both in the experimental and control group will continue receiving their usual typical care, formed by physiotherapy and any other form of therapy that the child requires, such as occupational therapy, speech therapy etc. It is anticipated that typical physiotherapy (alongside with hydrotherapy or horse riding) will constitute only 1-3 days per week sessions, otherwise it can be considered as an intensive physiotherapy program.

---

### Previous intervention:

The recruitment of the population will be carried out by private and public therapeutic areas. A group of children with ataxia, aged 8 to 18 years will participate.

Information sheet and consent form will be provided to all participants. After obtaining a signed consent form, subjects will be randomly assigned to either intervention group (functional PBWSTT) or control group (conventional physiotherapy).

Assessment will be obtained in three-time periods: prior to the experiment, after the experiment and 2 months after the experiment. For the anthropometric data acquisition precision equipment will be used. Gait training will be performed using a Lite Gait LGI 200P system accompanied by a Gait keeper Treadmill system with a low start walking speed (0.1m/h) and built-in sensors for data recording. Gait Sens 2000 and BiSym Software will be used. Gait and posture biomechanical data will be acquired by 10 Vicon Cameras (6MXT10 and 4 Verov2.2) at 100 Hz and 2 Basler (Pentax lenses) digital video cameras 50 Hz. Vicon Nexus 2.9.1 recording software for the 16 passive reflective markers gap-filling and data filtering will be used. Further processing and extraction of data will be made through Vicon Polygon 3.5.1 software.

### Functional based PBWSTT Intervention

The proposed protocol will be based on the implementation of the protocol of Bjornson et al. (2019) with modifications based on the findings of the literature, alongside functional dual-task activities. All the phases of the protocol will be administered in PBWS. The suspension will be set to <40% of body weight. Twenty 45-minute sessions will be completed over a period of 4-weeks (5 days per week). The period of 45 min will be composed of two phases:

1. Phase 1 (Gait treadmill training phase with PBWS). The treadmill gait training through short burst interval PBWSTT will last 30 total minutes. The speed of the treadmill will be individualized for each participant, employing baseline self-selected and fast walking speed over ground (10-m walk test), thus standardizing the dosing of training speeds for high and low-speed walking levels. Starting tread speeds for high and low walking treadmill speed will be 75-80% of each participant's baseline walking over-ground levels. High-speed and low-speed intervals will be alternated every 30 sec. High speed will be gradually increased by 5-10% within and between sessions, while low speed remains constant throughout the protocol. The child will be informed of the speed intervals during the gait.

2. Phase 2 (Functional dual kinetic training with PBWS). The Functional dual kinetic training will last 15 total minutes and will be delivered during constant low-speed gait on the treadmill (treadmill pace step). Functional exercises during gait will simulate the needs of daily life and they will consist of walking in different directions, steps to the side, back steps, walking and crossing obstacles, walking and catching and throwing a ball.

Subjects in the intervention group will continue their regular therapeutic program, alongside the control group.

### Intervention Type

Behavioural

### Primary outcome(s)

Current primary outcome measure as of 29/12/2021:

For the primary outcome measure there will be a first baseline assessment prior to the 4-week intervention period (pre), a 4-week post-assessment conducted by the end of the 4-week intervention period (4-week post) and a final 2-month post-assessment, conducted 2 months after the end of the 4-week intervention period (follow-up).

1. The Gross Motor Function Measure (GMFM-88) dimension D/E, will be expressed as percentage score (%) for assessment of the motor performance and functional ability in standing, walking, running and jumping. GMFM is considered the primary outcome measure, as this has been examined widely in pediatric population and can be affected positively after a therapeutic intervention. The change from pre to 4-week post of GMDF -D will be used as the primary endpoint for calculating the effect size, as this measure is more likely to be mostly affected.

---

Previous primary outcome measure as of 03/08/2021:

Measured at baseline, 1 month and 3 months. All measurements will be in regards to coordination of movements, upright posture, static and dynamic balance, gait, physical activity and gross functional ability and will include:

1. Gross Motor Function Measure Domain D and E (GMFM-88) for assessing functional skills
  2. 10 meters walking test for assessing walking cadence
  3. Pediatric Balance Scale
- 

Previous primary outcome measure:

Measured at baseline, 1 month and 3 months. All measurements will be in regards to coordination of movements, upright posture, static and dynamic balance, gait, physical activity and gross functional ability and will include:

1. SARA Scale of Assessing and Rating Ataxia for assessing ataxia
2. Gross Motor Function Measure Domain D and E (GMFM-88) for assessing functional skills
3. 10 meters walking test for assessing walking cadence
4. 6min Walk Test for assessing physical activity-endurance
5. Timed-Up and Go test for assessing walking speed and independent walking ability
6. Biomechanical balance and gait parameters through the equipment mainly specified by gait analysis lab and BiSym and GaitSens software through LiteGait and specific treadmill usage

### **Key secondary outcome(s)**

Current secondary outcome measures as of 29/12/2021:

Similarly, for secondary outcome measures there will be a first baseline assessment prior to the 4-week intervention period (pre), a 4-week post-assessment, conducted by the end of the 4-week intervention period (4-week post) and a final 2-months post-assessment, conducted 2 months after the end of the 4-week intervention period (follow-up)

1. Functional balance skills assessed using the Pediatric Balance Scale, with score ranging 0–56 (higher score indicates better balance)
  2. Gait speed assessed using the 10-m walk test on the treadmill
  3. Dynamic balance control assessed using the Timed Up and Go test
  4. Physical condition and endurance assessed using the 6-min walk test
  5. Ataxia severity assessed using the Scale for Assessment and Rating Ataxia (SARA), applied in the Greek version, with score range 0–40 (higher score indicates more severe ataxia)
  6. Spatiotemporal gait parameters assessed using GaitSens software through LiteGait and specific treadmill usage
  7. Three-dimensional kinematic and kinetic analysis of lower limbs through motion and gait analysis applied with electronic recording of kinematics elements for the pelvis, hip, knee and foot of both lower limbs in the three planes of motion (sagittal, frontal and transverse)
-

Previous secondary outcome measures as of 03/08/2021:

1. Anthropometric data: age, weight (kg), BMI (kg/m<sup>2</sup>), height (cm) and data regarding medical records will be assessed at baseline
  2. Quality of life measured using the Child quality of Life Questionnaire for child report measured at baseline.
- All other measurements will be assessed at baseline, 1 month and 3 months.
3. SARA Scale of Assessing and Rating Ataxia for assessing ataxia
  4. 6min Walk Test for assessing physical activity-endurance
  5. Timed-Up and Go test for assessing walking speed and independent walking ability
  6. Spatiotemporal gait parameters through GaitSens software through LiteGait and specific treadmill usage
  7. Three dimensional kinematic and kinetic analysis of lower limbs through motion and gait analysis applied with electronic recording of kinematics elements for the pelvis, hip, knee and foot of both lower limbs in the three planes of motion (sagittal, frontal and transverse).

---

Previous secondary outcome measures:

1. Anthropometric data: age, weight (kg), BMI (kg/m<sup>2</sup>), height (cm) and data regarding medical records will be assessed at baseline
2. Quality of life measured using the Child quality of Life Questionnaire for both child and parents at baseline, 1 month and 3 months
3. Balance measured using The Pediatric Balance Scale at baseline, 1 month and 3 months

### **Completion date**

20/03/2023

## **Eligibility**

### **Key inclusion criteria**

Current inclusion criteria as of 29/12/2021:

1. Ataxia as their primary motor disorder, as a result of congenital, acquired or genetic damage
2. Gross Motor Function Classification System (GMFCS) II-IV
3. Aged 8-18 years
4. Attendance of a physiotherapy program in an outpatient or community setting the last 6 months after a relevant medical admission
5. Willingness to participate in the study.

---

Previous inclusion criteria as of 03/08/2021:

1. Ataxia as their primary motor disorder, as a result of congenital, acquired or genetic damage
2. Gross Motor Function Classification System (GMFCS) II-IV
3. Age 8 - 18 years old
4. Attendance of a physiotherapy program after a relevant medical admission
5. Willingness to participate in the study

---

Previous inclusion criteria:

1. Aged 8 - 18 years
2. Gross Motor Function Classification System (GMFCS) II-III

3. Ataxia as their primary motor disorder, as a result of congenital, acquired or genetic damage
4. Attendance of a physiotherapy program after a relevant medical admission and
5. Willingness to participate in the study.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Lower age limit**

8 years

**Upper age limit**

18 years

**Sex**

All

**Total final enrolment**

21

**Key exclusion criteria**

Current exclusion criteria as of 29/12/2021:

1. Invasive neurological or orthopedic intervention, such as botox injection, alcohol block, muscle-tendon lengthening, or tendon transfer surgery within 6 months from the study
2. Coexisting degenerative disorders, such as arthrogyrosis
3. Significant heart or respiratory disease
4. Lower motor neuron disorder diagnosis, such as spinal muscular atrophy
5. Co-morbid conditions (not related to ataxia diagnosis) such as peripheral vascular disease and diabetic polyneuropathy
6. Coexisting musculoskeletal or rheumatoid disorder that prevents independent walking
7. Deficient ocular alertness
8. Cognitive impairments which restrict them from understanding commands, evidenced by their medical diagnosis or any kind of psychiatric disorder
9. Reluctance of parents to collaborate with the researchers for scheduling the timeframe of evaluations and/or intervention period

---

Previous exclusion criteria as of 03/08/2021:

1. invasive neurological or orthopedic intervention, such as botox injection, alcohol block, muscle-tendon lengthening, or tendon transfer surgery within 6 months from the study
2. coexisting degenerative disorders, such as Spinal Muscular Atrophy
3. significant medical heart or respiratory disease
4. lower motor neurons, such as sciatic nerve paralysis
5. co-morbid conditions such as peripheral vascular disease and diabetic polyneuropathy
6. coexisting musculoskeletal and rheumatoid disorder that prevents independent walking
7. deficient and/or ocular alertness

8. cognitive impairments which restrict them from understanding commands, evidenced by their medical diagnosis or any kind of psychiatric disorder

9. reluctant parents

---

Previous exclusion criteria:

1. Have undertaken invasive neurological or orthopedic intervention, such as botox injection, alcohol block, muscle-tendon lengthening, or tendon transfer surgery within 6 months from the study

2. Have coexisting degenerative disorders, such as Spinal Muscular Atrophy

3. Have significant medical heart or respiratory disease

4. Have Lower Motor Neurons, such as sciatic nerve paralysis

5. Have co-morbid conditions such as peripheral vascular disease and diabetic polyneuropathy

6. Have coexisting any musculoskeletal and rheumatoid disorder that prevents independent walking

7. Have deficient alertness

8. Are unable to understand commands as evidenced by their medical diagnosis or any kind of psychiatric disorder

9. Parents' are reluctant

**Date of first enrolment**

15/06/2021

**Date of final enrolment**

16/12/2022

## **Locations**

**Countries of recruitment**

Greece

**Study participating centre**

**Alexandra Lepoura**

67 Pentelis Str

Kinitro kai Kinisi

Marousi - Athens

Greece

15126

**Study participating centre**

**Elepap**

16, Kononos Str

Athens

Greece

11634

**Study participating centre**  
**Physiotherapy Lab Uniwa**  
28, Agiou Spyridonos  
Aigaleo  
Greece  
12243

## Sponsor information

**Organisation**  
University of West Attica

**ROR**  
<https://ror.org/00r2r5k05>

## Funder(s)

**Funder type**  
Other

**Funder Name**  
Investigator initiated and funded

## Results and Publications

### Individual participant data (IPD) sharing plan

Current IPD sharing statement as of 29/12/2021:

The datasets generated during and/or analysed during the current study will be available upon request from Alexandra Lepoura (alepoura@uniwa.gr). The individual participant data that underlie the results reported in the published article, after deidentification (text, tables, figures, and appendices), Study Protocol, Statistical Analysis Plan, Informed Consent Form, and Analytic Code will be available beginning 3 months and ending 6 years following article publication to researchers who provide a methodologically sound proposal in order to achieve the aims in the approved proposal. Proposals should be directed to alepoura@uniwa.gr. To gain access, data requestors will need to sign a data access agreement. Data will then be available for 6 years at a third-party website.

Information sheet and consent form will be provided to all participants. Signed consent form should be obtained prior to participants' enrollment to the study. The files with participants' results will be coded and personal data will not be published anywhere. The personal data collected from the experiment will be kept confidential and all data will be stored in the

researcher's computer (Alexandra Lepoura) where no unauthorised persons have access. Moreover, the files with the data will be protected by security codes and any data saved in papers will be locked in a special cupboard and only the researchers will have access to them.

---

#### Previous IPD sharing statement:

The datasets generated during and/or analysed during the current study are/will be available upon request from Alexandra Lepoura (alepoura@uniwa.gr). The individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices), Study Protocol, Statistical Analysis Plan, Informed Consent Form, and Analytic Code will be available beginning 3 months and ending 5 years following article publication to researchers who provide a methodologically sound proposal in order to achieve the aims in the approved proposal. Proposals should be directed to alepoura@uniwa.gr. To gain access, data requestors will need to sign a data access agreement. Data will then be available for 5 years at a third party website.

Information sheet and consent form will be provided to all participants. Signed consent form should be obtained prior to participants' enrollment to the study. The files with participants' results will be coded and personal data will not be published anywhere. The personal data collected of the experiment will be kept confidential and all data will be stored in the researcher's computer (Alexandra Lepoura) where no unauthorised persons have access. Moreover, the files with the data will be protected by security codes and any data saved in papers will be locked in a special cupboard and only the researchers will have access to them.

#### IPD sharing plan summary

Available on request

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		06/04/2025	10/04/2025	Yes	No
<a href="#">Protocol article</a>		25/03/2022	28/03/2022	Yes	No